Occam Places Two Board Members at George Church Biotech

In August 2025, Occam Global recruited Doug Williams, PhD, and Adam Craig, MD, PhD, to the eGenesis board.  

Douglas Williams, PhD, is a senior R&D leader with over 30 years of experience gained at Biogen, ZymoGenetics, Amgen, and Seagen, and has contributed to such notable therapies as Enbrel®, Tecfidera®, and Spinraza®. Williams was President of R&D at Sana Biotechnology and founding CEO of Codiak Biosciences. He now chairs Climb Bio and serves on the board of CAMP4 Therapeutics.

Adam Craig, MD, PhD, brings 25+ years of drug development and commercialization expertise in oncology, hematology, and rare diseases. As CEO of CTI BioPharma, he led Vonjo® to approval and commercialization and then sold that company to Swedish Orphan Biovitrum AB (Sobi) in 2023 for ~$1.7 billion. He now serves as Executive Chairman of X4 Pharmaceuticals and as a member of Stratus Therapeutics’ board. ‍

About eGenesis

eGenesis isa George Church company pioneering a genome engineering-based approach to develop safe and effective transplantable organs, ultimately ending the global organ shortage. In the last year, the company has successfully completed two porcine-human kidney transplants and is utilizing funds from a recently closed $191M Series D round to advance programs in the heart, liver, and kidney to the clinic. Investors include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Leaps by Bayer, Polaris Partners, Catalio Capital Management, and Osage University Partners.